Abstract
Although erythropoietin therapy has been available for the treatment of renal anemia for over a decade, there is still no general consensus on what the appropriate target hemoglobin to aim for is in patients with this condition [1–3]. Indeed, the question as to whether the anemia should be partially or fully corrected is arguably the most debated and controversial issue in this aspect of patient management. Why is this so? If one examines the scientific evidence relating to this topic, one can find both circumstantial evidence, and also evidence from intervention clinical trials [4–11].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Nissenson AR, Besarab A, Bolton WK. Target haematocrit during erythropoietin therapy. Nephrol Dial Transplantation. 1997;12:1813–16.
Ritz E, Amann K. Optimal haemoglobin during treatment with recombinant human erythropoietin. Nephrol Dial Transplantation. 1998;13(supplement 2): 16–22.
Jacobs C. Normalization of haemoglobin: why not? Nephrol Dial Transplantation. 1999;14(supplement 2):75–9.
Besarab A, Kline Bolton W, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.
Furuland H, Linde T, Danielson BG. Cardiac function in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin. J Am Soc Nephrol. 1998;9:337A.
Furuland H, Linde T, Danielson BG. Physical exercise capacity in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin. J Am Soc Nephrol. 1998;9:337A.
Stombom U, Ahlmen J, Danielson B. The Scandinavian Erythropoietin Study: effects on quality of life of normalizing hemoglobin levels in uremic patients. J Am Soc Nephrol. 1999;10:142.
Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–35.
Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335–42.
McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplantation. 1999;14:1182–7.
McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality-of-life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplantation. 2000;15:1425–30.
NKF-DOQI Work Group. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30(supplement 3): S192-S240.
European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplantation. 1999;14(supplement 5):l-50.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987;316:73–8.
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;i:1 175–8.
Macdougall IC. Should the hematocrit be normalized in dialysis and in pre-ESRD patients? Blood Purif. 2001;19:157–67.
Eschbach JW, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, Chandler W, Davidson R, Easterling T, Denney J, Schneider G. Normalizing the hematocrit in hemodialysis patients with EPO improves quality of life and is safe. J Am Soc Nephrol. 1993;4:425.
Macdougall IC, Ritz E. The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplantation. 1998;13:3030–3.
Barany P, Svedenhag J, Katzarski K, Divino Filno J, Norman R, Freyshuss U, Bergström J. Physiologic effects of correcting anemia in hemodialysis patients to a normal hemoglobin concentration. J Am Soc Nephrol. 1996;7:1472.
Stray-Gunderson J, Sams B, Goodkin D, Holloway D, Wang C, Thompson J. Improvement in functional capacity in dialysis patients with regular exercise and correction of anemia. J Am Soc Nephrol. 1997;8:112A.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–92.
Levin A, Thompson CR, Ethier J, Carlisle EJF, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34: 125–34.
Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000; 35:250–6.
Martinez-Vea A, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis. 1992;19:353–7.
Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J. 1990;300:573–8.
Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int. 1999;56:253–60.
Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Renal Failure. 2000;22:435–44.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Macdougall, I.C. (2002). Normalizing hematocrit in renal failure: dangerous or desirable?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_7
Download citation
DOI: https://doi.org/10.1007/978-94-015-9998-6_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-6045-7
Online ISBN: 978-94-015-9998-6
eBook Packages: Springer Book Archive